ClinicalTrials.gg
Active, not recruitingNCT05348733Updated Oct 16, 2026

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

An observational study in Chronic Kidney Disease and Type 2 Diabetes Mellitus, sponsored by Bayer. Active, not recruiting at 56 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Bayer · Observational

How we know

Updated Oct 16, 2026Primary completion moved18 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,613
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.

Enrollment
9th of 17
4,613 · median 4,613
Started
2022
with 8 others
Observational
17 of 49
3 open now
Registered
24th of 49
by date

Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 9th largest by enrollment of the 17 observational ones that give a count, is one of 9 that started in 2022, is one of 17 observational ones, and was the 24th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Renal Insufficiency, Chronic by Bayer, or all of them as a file.
02

Study summary

This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone.

Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a result, CKD can occur as a complication of T2D.

Finerenone works by blocking certain proteins, called mineralocorticoid receptors. An increased stimulation of these proteins is thought to damage the kidneys and the heart. By lowering their stimulation, finerenone reduces the risk of kidney disease progressively getting worse.

Finerenone is available and approved for doctors to prescribe to people with CKD and T2D. Since it has only recently become available for these patients, there is a need for more information about the use of finerenone in the real-world setting.

The main purpose of the study is to learn more about treatment patterns in people with CKD and T2D who just started or will start finerenone treatment as decided and prescribed by their doctor as part of their routine medical care.

To answer this question, the researchers will collect data on:

  • Clinical characteristics (e.g., history of CKD and T2D, blood pressure, heart health) of the participants
  • Reasons for starting finerenone
  • Reasons for stopping finerenone early
  • How long participants have been taking finerenone (planned by their doctor compared to actual time it was taken)
  • Dosing of finerenone
  • Other medications used while taking finerenone

The researchers will also collect data on medical problems (called adverse events) that the participants may have during the study. All adverse events are collected, even if they might not be related to the study treatment.

Hyperkalemia, a medical term used to describe a potassium level in the blood that is higher than normal, is of special interest when finerenone is combined with some medications commonly taken to control blood pressure. Researchers want to know how often higher potassium levels occur, and when it leads to:

  • Stopping finerenone treatment too early
  • Dialysis (a medical procedure to filter the blood of extra water and waste)
  • Care in a hospital

All data will come from medical records or from interviews study doctors will have with the participants during visits that take place during routine medical care.

Participants in the US will be invited to provide voluntary blood and urine samples that could be analyzed later to better understand possible changes in protein or nucleic acid levels over time.

Each participant will be in the study for 12 months. This time participating in the study may be shorter if their finerenone treatment is stopped early or the study comes to an end as planned in September 2027.

03

Conditions studied

  • Chronic Kidney Disease
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with a diagnosed of CKD and T2D will be enrolled after the decision for treatment with finerenone has been made by the treating physician.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants of all genders (≥18 years old)
  • Diagnosis of CKD associated with T2D based on assessment by physician.
  • Treatment according to local marketing authorization, finerenone 20 or 10 mg.Treatment should have been started up to 8 weeks before or after the ICF is signed.
  • Decision to initiate treatment with finerenone must be made before ICF is signed.
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Participation in an trial at any time during the course of this study
  • according to the local label.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,613 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants diagnosed with CKD and T2D

    Participants who are newly prescribed finerenone under routine treatment conditions.

    Drug: Kerendia (Finerenone, BAY94-8862)

Interventions

  • DrugFinerenoneStudies of FinerenoneFinerenone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Decision will taken by the treating physician to initiate treatment with finerenone.

06

What researchers measure

Primary outcomes

  1. Descriptive analysis of clinical characteristics of participants with chronic kidney disease (CKD) and with type 2 diabetes(T2D).

    Time frame: Approximately 62 months

  2. Descriptive summary of reasons for introducing finerenone.

    Time frame: Approximately 62 months

  3. Descriptive summary of reasons for discontinuation of finerenone.

    Time frame: Approximately 62 months

  4. Planned and actual duration of treatment with finerenone

    Time frame: Approximately 62 months

  5. Planned and actual daily dose of finerenone treatment

    Time frame: Approximately 62 months

  6. Planned and actual frequency of finerenone treatment

    Time frame: Approximately 62 months

  7. Descriptive summary of secondary therapies used in participants with CKD and T2D.

    Time frame: Approximately 62 months

Secondary outcomes

  1. Occurrence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Approximately 62 months

  2. Occurrence of hyperkalemia

    leading to permanent study drug discontinuation, dialysis or hospitalization

    Time frame: Approximately 62 months

Other outcomes

  1. Descriptive summary for healthcare resource utilization.

    Time frame: Approximately 62 months

  2. Occurrence of newly diagnosed diabetic retinopathy or progression of existing disease at treatment initiation

    Time frame: Approximately 62 months

07

Study locations

56 sites
  • Nephrology Consultants LLC
    Huntsville, Alabama 35805, United States
  • AKDHC Medical Research Servies LLC
    Phoenix, Arizona 85016, United States
  • Harrisburg Family Medical Center
    Harrisburg, Arkansas 72432, United States
  • Kidney Disease Medical Group
    Glendale, California 91206, United States
  • Renal Consultants Medical Group
    Granada Hills, California 91344, United States
  • University of Central Florida College of Medicine
    Orlando, Florida 32817, United States
  • Gulf View Medical
    Port Charlotte, Florida 33952, United States
  • Hanson Clinical Research Center
    Port Charlotte, Florida 33952, United States
  • Metabolic Research Institute
    West Palm Beach, Florida 33401, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Coastal Medical Research
    Brunswick, Georgia 31523, United States
  • Caritas Medical Center
    Stockbridge, Georgia 30281, United States
  • Herman Clinical Research LLC
    Suwanee, Georgia 30024, United States
  • Laurie Tom, MD
    Honolulu, Hawaii 96813, United States
  • Pacific Diabetes & Endocrine Center
    Honolulu, Hawaii 96813, United States
  • Medico
    Chicago, Illinois 60616, United States
  • Nephrology Associates Northern Illinois and Indiana
    Hinsdale, Illinois 60521, United States
  • Kidney and Hypertension Center of Wabash Valley LLC
    Terre Haute, Indiana 47804, United States
  • Ochsner Medical Foundation
    Slidell, Louisiana 70461, United States
  • University of Maryland Midtown Professionals Group Healthcare
    Baltimore, Maryland 21201, United States
  • NECCR Primacare Research, LLC
    Fall River, Massachusetts 02721, United States
  • Healthy Heart Cardiology
    Grand Rapids, Michigan 49546, United States
  • Care Access Research - Minneapolis
    Minneapolis, Minnesota 55403, United States
  • Nephrology and Hypertension Associates
    Tupelo, Mississippi 38801, United States
  • Renown Regional Medical Center
    Reno, Nevada 89502, United States
  • The EnLyv Clinics
    Edison, New Jersey 08820, United States
  • Gaffney Health Services
    Charlotte, North Carolina 28205, United States
  • Bland Clinic
    Greensboro, North Carolina 27401, United States
  • Ardmore Medical Research
    Winston-Salem, North Carolina 27103, United States
  • Panoramic Health
    Providence, Rhode Island 02904, United States
  • DarSalud Care / LifeDOC Research
    Memphis, Tennessee 38119, United States
  • Academy of Diabetes Thyroid and Endocrine
    El Paso, Texas 79935, United States
  • AA Medical Research Center
    Flint, Texas 48504, United States
  • Clinical Research Stategies Inc
    Houston, Texas 77090, United States
  • RGV Endocrine Center
    McAllen, Texas 78503, United States
  • Dallas Renal Group
    Plano, Texas 75093, United States
  • Tranquil Clinical Research
    Webster, Texas 77598, United States
  • MultiCare Endocrinology Specialists Tacoma
    Tacoma, Washington 98405, United States
  • Many Locations
    Many Locations, Argentina
  • Many Locations
    Many Locations, Belgium
  • Many Locations
    Many Locations, Brazil
  • Many Locations
    Many Locations, Canada
  • Many Locations
    Many Locations, China
  • Many Locations
    Many Locations, Denmark
  • Many Locations
    Many Locations, Germany
  • Many Locations
    Many Locations, Greece
  • Many Locations
    Many Locations, Mexico
  • Many Locations
    Many Locations, Netherlands
  • Many Locations
    Many Locations, Portugal
  • Many Locations
    Many Locations, Saudi Arabia
  • Many Locations
    Many Locations, Singapore
  • Many Locations
    Many Locations, Slovenia
  • Many Locations
    Many Locations, South Korea
  • Many Locations
    Many Locations, Switzerland
  • Many Locations
    Many Locations, Taiwan
  • Many Locations
    Many Locations, Thailand
08

References and documents

Publications

  • Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Vaduganathan M, Agarwal R; CONFIDENCE Trial Investigators. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. 2026 Apr 1;37(4):764-776. doi: 10.1681/ASN.0000000928. Epub 2025 Nov 6. PubMed 41196655 ↗
  • Desai NR, Navaneethan SD, Nicholas SB, Pantalone KM, Wanner C, Hamacher S, Gay A, Wheeler DC. Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice. J Diabetes Complications. 2023 Apr;37(4):108411. doi: 10.1016/j.jdiacomp.2023.108411. Epub 2023 Feb 2. PubMed 36857997 ↗

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Sep 2026, 51 months.

Of 51 industry-sponsored observational studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 51. This study's 51 months is above that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Sep 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2022
First posted
Apr 27, 2022
StartActual
Jun 13, 2022
Primary completionActual
Sep 28, 2026was Nov 2026
CompletionEst.
Dec 22, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
18 sites added, 18 sites removed
Show 18 added (1 Argentina, 1 Belgium, 1 Brazil, 1 Canada, 1 China, 1 Denmark, 1 Germany, 1 Greece, 1 Mexico, 1 Netherlands, 1 Portugal, 1 Saudi Arabia, 1 Singapore, 1 Slovenia, 1 South Korea, 1 Switzerland, 1 Taiwan, 1 Thailand)
  • Many Locations · Many Locations, Argentina
  • Many Locations · Many Locations, Belgium
  • Many Locations · Many Locations, Brazil
  • Many Locations · Many Locations, Canada
  • Many Locations · Many Locations, China
  • Many Locations · Many Locations, Denmark
  • Many Locations · Many Locations, Germany
  • Many Locations · Many Locations, Greece
  • Many Locations · Many Locations, Mexico
  • Many Locations · Many Locations, Netherlands
  • Many Locations · Many Locations, Portugal
  • Many Locations · Many Locations, Saudi Arabia
  • Many Locations · Many Locations, Singapore
  • Many Locations · Many Locations, Slovenia
  • Many Locations · Many Locations, South Korea
  • Many Locations · Many Locations, Switzerland
  • Many Locations · Many Locations, Taiwan
  • Many Locations · Many Locations, Thailand
Show 18 removed
  • Many Locations · Multiple Locations, Argentina
  • Many Locations · Multiple Locations, Belgium
  • Many Locations · Multiple Locations, Brazil
  • Many Locations · Multiple Locations, Canada
  • Many Locations · Multiple Locations, China
  • Many Locations · Multiple Locations, Denmark
  • Many Locations · Multiple Locations, Germany
  • Many Locations · Multiple Locations, Greece
  • Many Locations · Multiple Locations, Mexico
  • Many Locations · Multiple Locations, Netherlands
  • Many Locations · Multiple Locations, Portugal
  • Many Locations · Multiple Locations, Saudi Arabia
  • Many Locations · Multiple Locations, Singapore
  • Many Locations · Multiple Locations, Slovenia
  • Many Locations · Multiple Locations, South Korea
  • Many Locations · Multiple Locations, Switzerland
  • Many Locations · Multiple Locations, Taiwan
  • Many Locations · Multiple Locations, Thailand
Oct 16, 2026
Primary completion
Nov 5, 2026→Sep 28, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    18 sites added, 18 sites removed
    Show 18 added (1 Argentina, 1 Belgium, 1 Brazil, 1 Canada, 1 China, 1 Denmark, 1 Germany, 1 Greece, 1 Mexico, 1 Netherlands, 1 Portugal, 1 Saudi Arabia, 1 Singapore, 1 Slovenia, 1 South Korea, 1 Switzerland, 1 Taiwan, 1 Thailand)
    • Many Locations · Many Locations, Argentina
    • Many Locations · Many Locations, Belgium
    • Many Locations · Many Locations, Brazil
    • Many Locations · Many Locations, Canada
    • Many Locations · Many Locations, China
    • Many Locations · Many Locations, Denmark
    • Many Locations · Many Locations, Germany
    • Many Locations · Many Locations, Greece
    • Many Locations · Many Locations, Mexico
    • Many Locations · Many Locations, Netherlands
    • Many Locations · Many Locations, Portugal
    • Many Locations · Many Locations, Saudi Arabia
    • Many Locations · Many Locations, Singapore
    • Many Locations · Many Locations, Slovenia
    • Many Locations · Many Locations, South Korea
    • Many Locations · Many Locations, Switzerland
    • Many Locations · Many Locations, Taiwan
    • Many Locations · Many Locations, Thailand
    Show 18 removed
    • Many Locations · Multiple Locations, Argentina
    • Many Locations · Multiple Locations, Belgium
    • Many Locations · Multiple Locations, Brazil
    • Many Locations · Multiple Locations, Canada
    • Many Locations · Multiple Locations, China
    • Many Locations · Multiple Locations, Denmark
    • Many Locations · Multiple Locations, Germany
    • Many Locations · Multiple Locations, Greece
    • Many Locations · Multiple Locations, Mexico
    • Many Locations · Multiple Locations, Netherlands
    • Many Locations · Multiple Locations, Portugal
    • Many Locations · Multiple Locations, Saudi Arabia
    • Many Locations · Multiple Locations, Singapore
    • Many Locations · Multiple Locations, Slovenia
    • Many Locations · Multiple Locations, South Korea
    • Many Locations · Multiple Locations, Switzerland
    • Many Locations · Multiple Locations, Taiwan
    • Many Locations · Multiple Locations, Thailand
    Primary completion Nov 5, 2026→Sep 28, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05348733
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
Jun 13, 2022
Primary completion
Sep 28, 2026
Completion
Dec 22, 2026 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion